NCT06680115尚未招募2 期
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma: a Multicenter, Open-label, Randomized Phase II Clinical Trial
First Affiliated Hospital of Guangxi Medical University1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2024年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Failure-free survival
研究概览
简要总结
To evaluate the efficacy and safety of neoadjuvant and adjuvant Sintilimab combined with chemoradiotherapy versus chemoradiotherapy alone in stage TanyN3M0 nasopharyngeal carcinoma. The primary endpoint was 2-year failure-free survival (FFS). Secondary endpoints included 2-year overall survival (OS), distant failure-free survival (DFFS), locoregional failure-free survival (LRFFS), and adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma;
- •Age≥18 years;
- •Staging TanyN3M0 (AJCC/UICC 9th edition) ;
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
- •White blood cell≥3.5×10^9/L,Neutrophils≥1.5×10^9/L, hemoglobin≥ 90 g/L, platelet (PLT)≥ 100x10^9/ L ;
- •Transaminases≤2.5 times the upper limit of normal, total bilirubin <1.5 times the upper limit of normal;
- •Creatinine clearance ≥60 ml/min;
- •Signed informed consent form.
排除标准
- •HBsAg positive and HBV DNA >1×103 copy/ml;
- •Patients with positive HCV antibody test results;
- •Active, known, or suspected autoimmune disease. Participants with type 1 diabetes, hypothyroidism requiring hormone replacement therapy, and skin conditions that do not require systemic treatment, such as vitiligo, psoriasis, or hair loss, may be enrolled;
- •History of interstitial lung disease;
- •Received systemic sex hormone or other immunosuppressive therapy with equivalent dose > 10mg prednisone/day within 28 days before signing the informed consent. Participants with a systemic sex hormone dose ≤10mg prednisone/day or inhaled/topical corticosteroids were enrolled;
- •Have received or will receive live vaccine within 30 days before signing the informed consent;
- •Pregnant or lactating women (pregnancy tests should be considered for sexually active, fertile women);
- •Had other malignancies within 5 years, except carcinoma in situ, adequately treated non-melanoma skin cancer, and papillary thyroid cancer;
- •The subject is known to have a prior allergy to macromolecular protein preparations, or any of the components of sindillizumab;
- •Human immunodeficiency virus (HIV) infection;
- •Other conditions, as determined by the investigator, that may affect subjects' safety or compliance with the study include symptomatic heart failure, unstable angina pectoris, myocardial infarction, active infection requiring systemic treatment, mental illness, or family and social factors.
研究组 & 干预措施
Sintilimab
Experimental
干预措施: Sintilimab (Drug)
结局指标
主要结局
Failure-free survival
时间窗: 2 years
次要结局
- Overall survival(2 years)
- Distant failure-free survival(2 years)
- Locoregional failure-free survival(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung CancerNon-small Cell Lung CancerNCT05170581The Second Affiliated Hospital of Shandong First Medical University30
招募中
2 期
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.Advanced Esophageal Squamous Cell CancerNCT05323890Shandong Cancer Hospital and Institute15
招募中
2 期
Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric CancerGastric CancerNCT06054906Huashan Hospital50
Unknown
2 期
Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast CancerBreast CancerNCT04722718Jiuda Zhao34
招募中
2 期
A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT06463834Fujian Cancer Hospital30